PHARMACEUTICAL FOR TREATING EYE DISEASE, LUNG DISEASE OR ATHEROSCLEROSIS BY REMOVING SENESCENT CELL FROM MORBID TISSUE

• Main Authors: DARREN J BAKER, ALBERT DAVALOS, JENNIFER ELISSEEFF, KIM CHAEKYU, JEON OKHEE, TAMAR TCHKONIA, JAN M A VAN DEURSEN, REMI-MARTIN LABERGE, ZHU YI, JAMES L KIRKLAND, ALAIN PHILIPPE VASSEROT, NATHANIEL DAVID, JUDITH CAMPISI, BENNETT G CHILDS, MARCO DEMARIA
• Format: Patent
• Language: English; Japanese
• Published: 29.08.2019
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MUTATION OR GENETIC ENGINEERING; PHYSICS; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROCESSES OF PREPARING SUCH COMPOSITIONS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; TESTING; VINEGAR; WINE

To provide a method for selectively killing senescent cells and treating a senescence-associated disease or disorder, comprising administering a senolytic agent.SOLUTION: The senolytic agent is selected from: an MDM2 inhibitor; an inhibitor of one or more BCL-2 anti-apoptotic protein family members wherein the inhibitor inhibits at least BCL-xL; and an Akt specific inhibitor. The senescence-associated disease or disorder that can be treated by a method using the senolytic agent include a cardiovascular disease or disorder associated with or caused by arteriosclerosis such as atherosclerosis, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease, osteoarthritis, senescence-associated eye disease or disorder, and senescence-associated skin disease or disorder.SELECTED DRAWING: Figure 8 【課題】老化細胞を選択的に殺すとともに老化に関連する疾患または障害を処置するための、老化細胞破壊薬剤投与を含む方法の提供。【解決手段】老化細胞破壊薬剤はＭＤＭ２阻害剤；少なくともＢＣＬ−ｘＬを阻害する１以上のＢＣＬ−２抗アポトーシスタンパク質ファミリーメンバーの阻害剤；および、Ａｋｔ特異的阻害剤から選択される。老化細胞破壊薬剤を用いる方法により処置可能な老化に関連する疾患または障害は、アテローム性動脈硬化などの動脈硬化症、特発性肺線維症、慢性閉塞性肺疾患、変形性関節症、老化に関連する眼疾患および障害、ならびに老化に関連する皮膚疾患または障害に関連付けられる、またはこれらによって引き起こされる心臓の疾患または障害を含む。【選択図】図８